Search Results for "CT P6 Celltrion"

11:07 EST 20th January 2017 | BioPortfolio

Matching Channels


Matching News

Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership

NewsTeva Pharmaceutical Industries Ltd., Celltrion, Inc., and Celltrion Healthcare announce that the companies have entered into an exclusive partnership to commercialize two of Celltrion’s mAb bios...

Teva, Celltrion partner on biosimilar commercialization

David SalazarTeva and Celltrion on Thursday announced a new exclusive partnership centered on commercializing two of Celltrion’s biosimilar candidates in the United States and Canada.  read...

Teva, Celltrion Announce Biosimilar Commercial Partnership

PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA), Celltrion Inc. and Celltrion Healthcare announced that they have entered into an exclusive partnership to commercialize two of C...

Teva and Celltrion to partner on biosimilars

Israeli generics giant Teva Pharmaceutical Industries (Teva) and South Korean biotechnology company Celltrion announced on 7 October 2016 that they had entered into an exclusive partnership for two of...

BRIEF-Celltrion signs 149.10 bln won contract with Celltrion Healthcare

* Says it signs 149.10 billion won contract with Celltrion Healthcare to sell remsima

Celltrion seeks to introduce more biosimilars in US

More biosimilars from a South Korean drugmaker could join Celltrion's Remicade biosimilar Inflectra, or Remsima, in the US ma -More- 

BRIEF-Teva and Celltrion report exclusive biosimilar commercial partnership

* Teva and Celltrion healthcare will share profit from commercialization of mab biosimilars

Teva partners with Celltrion in $150 million MAb biosimilars deal

Teva Pharmaceutical Industries has entered into an exclusive partnership with South Korea’s Celltrion…

Matching PubMed Articles

Search Whole site using Google

Quick Search
Advertisement Advertisement